Human corticotropin-releasing hormone improves overnight FEV1 in nocturnal asthma.


Journal Article

Corticotropin-releasing hormone (CRH) exhibits anti-inflammatory properties independent of its effect on adrenal function. We investigated the safety and effect of CRH in nocturnal asthma, a disease where inflammation is prominent. Five subjects underwent an overnight infusion of placebo on the first night, CRH at a 2.5 micrograms/kg/hr on the second night, and three subjects received CRH at 4.0 micrograms/kg/hr on the third night. A significant improvement occurred in overnight change in forced expiratory volume 1 sec. % (delta FEV1) with CRH (+17.4 +/- 9.1%) as opposed to placebo (-25.9 +/- 7.1%), p = 0.024, CRH was well tolerated. Further research with CRH may clarify the pathophysiology of nocturnal asthma.

Full Text

Cited Authors

  • Georges, G; Kraft, M; Vianna, EO; Martin, RJ

Published Date

  • January 1998

Published In

Volume / Issue

  • 35 / 3

Start / End Page

  • 261 - 265

PubMed ID

  • 9661678

Pubmed Central ID

  • 9661678

Electronic International Standard Serial Number (EISSN)

  • 1532-4303

International Standard Serial Number (ISSN)

  • 0277-0903

Digital Object Identifier (DOI)

  • 10.3109/02770909809068216


  • eng